The paraprotein as a tumor specific marker in plasmacytoma
Mohr, R.
Verhandlungen der Deutschen Gesellschaft für Innere Medizin 84: 196-198
1978
ISSN/ISBN: 0070-4067 PMID: 742044 Document Number: 125283
Document emailed within 1 workday
Related Documents
Zurborn, K.H.; Sondermann, I.; Gross, W.L. 1985: Decrease of paraprotein secretion despite progressive tumor cell proliferation by cytostatic drug therapy of plasmacytoma Der Internist 26(9): 584-586Maruno, K. 1990: Gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma, compared with neuron-specific enolase Nihon Geka Gakkai Zasshi 91(6): 760-765
Kim, B.S. 1979: Tumor-specific immunity induced by somatic hybrids. II. Elicitation of enhanced immunity against the parent plasmacytoma Journal of Immunology 123(2): 739-744
Ariyoshi, Y. 1984: Evaluation of neuron-specific enolase as a new tumor marker for carcinoma of the lung Gan no Rinsho. Japan Journal of Cancer Clinics 30(6 Suppl): 569-573
Rodríguez Duarte, C. 1991: Prostate-specific antigen as a prostatic tumor marker. Analysis of results in 206 patients Archivos Espanoles de Urologia 44(6): 697-700
Seno, H.; Yamaga, Y.; Nakanishi, Y.; Chiba, T. 2015: A tumor stem cell-specific marker identified by lineage tracing in the intestine Nihon Rinsho. Japanese Journal of Clinical Medicine 73(5): 850-854
Yonei, T.; Ohnoshi, T.; Hiraki, S.; Yamashita, H.; Ishii, J.; Egawa, T.; Kozuka, A.; Moritaka, T.; Uji, H.; Yoshida, M. 1988: Clinical evaluation of serum neuron-specific enolase as a tumor marker in lung cancer Nihon Kyobu Shikkan Gakkai Zasshi 26(2): 139-144
Kamachi, S.; Sakurabayashi, I.; Kawai, T. 1984: Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer Rinsho Byori. Japanese Journal of Clinical Pathology 32(7): 781-785
Leewansangtong, S.; Soontrapa, S.; Tantiwong, A. 1999: Is prostate-specific antigen still the best tumor marker for prostate cancer? Journal of the Medical Association of Thailand 82(10): 1034-1040
Schirrmacher, V.; von Hoegen, P.; Heicappell, R. 1989: Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells Progress in Clinical and Biological Research 288: 391-399
Rahman, S.M.; Kawashima, K.; Nakashima, I.; Nagase, F. 1988: Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210 Cancer Research 48(22): 6450-6454
Lubet, R.A.; Carlson, D.E. 1978: Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity Journal of the National Cancer Institute 60(5): 1107-1111
Mokuno, K.; Riku, S.; Matsuoka, Y.; Sobue, I.; Kato, K. 1983: Serum muscle-specific enolase levels in neuromuscular diseases--possibility as a new specific marker for muscular disorders Rinsho Shinkeigaku 23(10): 852-860
Loze, S.; Bercovici, D.; Lorin, J.L.; Lescene, R.; De Mascarel, A.; Masson, B. 1995: A rare tumor of the liver: solitary plasmacytoma Gastroenterologie Clinique et Biologique 19(11): 960-961
Hiramoto, R.N.; Ghanta, V.K.; Soong, S.J.; Hurst, D.C. 1977: An experimental approach to relate a tumor-associated enzyme marker to tumor cell numbers Cancer Research 37(2): 365-368
Oremek, G.M.; Teigelkamp, S.; Kramer, W.; Eigenbrodt, E.; Usadel, K.H. 1999: The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma Anticancer Research 19(4a): 2599-2601
Byrd, L.G.; McDonald, A.H.; Gold, L.G.; Potter, M. 1991: Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane Journal of Immunology 147(10): 3632-3637
Kos, T.; Aksoy, S.; Sendur, M.A.N.; Arik, Z.; Civelek, B.; Kandemir, N.; Ozdemir, N.Y.; Zengin, N.; Altundag, K. 2013: Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes Journal of BUON: Official Journal of the Balkan Union of Oncology 18(3): 608-613
Oremek, G.M.; Rutner, F.; Sapoutzis, N.; Sauer-Eppel, H. 2003: Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy Anticancer Research 23(2a): 1155-1158
Hardt, P.D.; Ngoumou, B.K.; Rupp, J.; Schnell-Kretschmer, H.; Kloer, H.U. 2000: Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer Anticancer Research 20(6d): 4965-4968